KCT0001897已完成未知
The Pilot Study on the Efficacy and Safety of Acupuncture and Analgesics against Cancer Pain in Advanced Cancer Patients
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1. Age 19-80
- •2. Advanced cancer stage with only palliative treatments available
- •3. Analgesic medication due to cancer pain
- •4. Eastern Cooperative Oncology Group performance status 0-2
- •5. Life expectancy more than 6 months
- •6. Voluntary agreement with the study protocols
排除标准
- •1. Hypersensitivity reaction after acupuncture
- •2. Pregnant or breast-feedingwoman, expectant mother
- •3. The protocol writting or hospital visits deemed to be hard
- •4. Other finds by Investigators are inadequate for the the clinical protocols
研究者
相似试验
尚未招募
不适用
Evaluation of the effectiveness and safety of acupoint pressure stimulation paste in preventing urinary retention after laparoscopic cholecystectomyaparoscopic cholecystectomyITMCTR2200006494Department of biliary tract sugery, West China Hospital of Sichuan University
招募中
不适用
A pilot study of efficacy and safety of aprepitant with chemoradiotherapy involving weekly cisplatin in patients with cervical cancer.cervical cancerJPRN-UMIN000003979ara Medical University30
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-BEAcerta Pharma, BV60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-GBAcerta Pharma B.V.60
进行中（未招募）
1 期
A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyHigh Risk Chronic Lymphocytic LeukemiaMedDRA version: 19.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-005317-68-ESAcerta Pharma, BV80